Novartis notes that it isn't expecting to complete the spinoff of Alcon anytime soon. The company still have to go through regulators and get more opinions about the process. It will also be seeking shareholder approval at its annual meeting in February 2019. If all goes well, it hopes to complete the spinoff in the first half of 2019.